Abstract
Primary hepatic amyloidosis (PHA) is extremely uncommon and usually associated with poor prognosis due to the development of decompensation. Therapy for this condition is liver transplantation (LT) and subsequent stem cell transplantation (SCT)(1). Nonetheless, because the liver disease can progress rapidly and liver donation is limited, patients may die before transplantation.
This article is protected by copyright. All rights reserved.
https://ift.tt/2SSsFHc
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.